Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

Genasense Plus Temodar(R) and Abraxane(R) Show Promising Early Clinical

Activity

BERKELEY HEIGHTS, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced the presentation of clinical data using the Company's lead oncology drug, Genasense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; Abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid translation of preclinical results that demonstrated marked anticancer synergy with this drug combination. The results will be presented by Dr. Anna C. Pavlick, New York University School of Medicine, at the Chemotherapy Foundation Symposium XXV, entitled "Innovative Cancer Therapy for Tomorrow", at the Marriott Hotel, New York, NY on November 9, 2007.

To date, 8 patients have been accrued to this trial. Of the first 7 evaluable patients, 5 patients have demonstrated clinical benefit, including 3 partial responses that occurred after the first treatment cycle, which have lasted for 40, 24 and 16 weeks, respectively. Two other patients have maintained stable disease lasting for a minimum of 24 weeks. Two patients had progressive disease, and one patient is too early to evaluate. There have been no episodes of Grade 4 (i.e., life-threatening) side-effects. Four patients experienced Grade 3 leukopenia (i.e., reduction in white blood cell count), and 1 patient had Grade 3 thrombocytopenia (i.e., reduction in platelet count).

"Our goal with this trial is to evaluate the synergy of Genasense with drugs other t
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 23, 2014 ViaDerma, Inc ... company devoted to bringing new products to market, ... , ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/25/2014)... Va. (PRWEB) October 24, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announces its appointment of four ... Workgroup. The workgroup leaders include:, , ... ,     Erik Pupo, Specialist Leader, Deloitte Consulting ...
(Date:10/25/2014)... A new way to produce engineered skin ... skin grafting technologies, it also speeds up the healing ... in the October issue of STEM CELLS Translational Medicine, ... that result from severe burns and chronic wounds. , ... elements. These wounds heal by contraction, with epithelization (the ...
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... ), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking ... , , Date:  May ... Time:  8:30am Pacific Time , , , ... , , ...
... HONG KONG , May 10 /PRNewswire-FirstCall/ ... Cypress Biosciences ("Cypress"), its development partner for Indaflex, that ... the termination of all Indaflex activity in the ... Chinese market. AlphaRx is working diligently with its regulatory ...
... NEW YORK , May 10 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical,company dedicated to improving health through the development, manufacture and,commercialization of a broad ... the first quarter ended March,31, 2010 . , ... First Quarter 2010 Financial Performance , ...
Cached Biology Technology:Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 3American Oriental Bioengineering Reports First Quarter 2010 Financial Results 4American Oriental Bioengineering Reports First Quarter 2010 Financial Results 5American Oriental Bioengineering Reports First Quarter 2010 Financial Results 6American Oriental Bioengineering Reports First Quarter 2010 Financial Results 7American Oriental Bioengineering Reports First Quarter 2010 Financial Results 8
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... next five years for a pilot project to assess ... conditions can and should become a routine part of ... launched today by the National Institutes of Health to ... as part of, or instead of, the current newborn screening ...
... September 5, 2013, Shenzhen, China BGI in collaboration ... other Chinese institutes, have completed the genome sequencing of ... infectious disease tuberculosis (TB). The study published online in ... researchers to better understand the genetic basis underlying drug ...
... known for some time that the blood vessels that transport ... are more than just bodily pipelines. Arterioles and capillaries, the ... flow of the blood they,re carrying. Biomedical engineers at Drexel ... that explains just how they do it. The team, ...
Cached Biology News:UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4Drug resistance-associated genes: A cornerstone for the control and protection against tuberculosis 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
ANTI PIG LDH H4...
... ideal for use in refrigerators, freezers, or liquid nitrogen. ... colors allow for color coding to project, user, lab, ... or promote cool air circulation. Supplied with 10 x ... Box dimensions: 13 x 13 x 5.1 ...
Biology Products: